Vaxart raises $10M via registered direct offering of 15.4M shares at $0.65/share

Vaxart, Inc.

Sold 15,384,615 shares to RA Capital Management at $0.65 per share for gross proceeds of $10.0M.
Proceeds to be used for general corporate purposes including working capital and operating expenses.
Offering is expected to close on or about January 18, 2024, subject to customary conditions.
Shares are offered under an existing shelf registration statement on Form S-3.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vaxart, Inc. entered into Securities Purchase Agreement with RA Capital Healthcare Fund, L.P valued at approximately $10 million (effective 2024-01-16).

Action: entry
Agreement: equity purchase
Counterparty: RA Capital Healthcare Fund, L.P
Value: approximately $10 million
Effective: 2024-01-16

Exact text from the filing

On January 16, 2024, Vaxart, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with RA Capital Healthcare Fund, L.P (“RA Capital”).

View on SEC.gov

Browse all material agreements →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-001419

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.